Robust T cell responses have been associated with milder outcomes in many infections. T
cells also establish long-term memory pools and, as they are predominantly directed toward …

Although COVID-19 outcomes have improved over the pandemic for patients with RA, some
experience poor acute and postacute outcomes after COVID-19. Clinicians and patients …

Background Concerns have been raised regarding the reduced immunogenicity of vaccines
against COVID-19 in patients with autoimmune diseases treated with rituximab. However …

Background Some patients with systemic autoimmune rheumatic disease and
immunosuppression might still be at risk of severe COVID-19. The effect of outpatient SARS …

Background Rheumatoid arthritis has been associated with severe COVID-19, but few
studies have investigated how phenotypes of rheumatoid arthritis affect these associations …

Objective Patients with immune‐mediated inflammatory diseases (IMIDs) receiving B cell–
depleting therapy (BCDT) are among the most vulnerable to severe COVID‐19, as well as …

Methods All Cleveland Clinic healthcare system pharmacy records were electronically
searched for patients with IMIDs or IEI who met the criteria to receive tixagevimab/cilgavimab …

The antineutrophil cytoplasmic antibody (ANCA)–associated vasculitides (AAV) comprise a
major subset of diseases that cause destructive inflammation of small and medium‐sized …

It has been over a year since people with multiple sclerosis (pwMS) have been receiving
vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With a …

Follicular lymphoma is the most common indolent non-Hodgkin's lymphoma, and because of
the incurable nature of this disorder, new therapies are constantly needed. The recently …